<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225325</url>
  </required_header>
  <id_info>
    <org_study_id>P25-INACTION</org_study_id>
    <nct_id>NCT04225325</nct_id>
  </id_info>
  <brief_title>Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).</brief_title>
  <acronym>P25-INACTION</acronym>
  <official_title>Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI) Treated With Multitarget Antiviral Therapy (MT-ART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADRIANO LAZZARIN, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministero della Salute, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, parallel group, randomised, open label, study. Twenty-five clinical centers&#xD;
      constituting the InAction network will participate the study.&#xD;
&#xD;
      Eligible patients will be randomised in a ratio 10:10:8 to be treated with one of the three&#xD;
      antiretroviral regimens:&#xD;
&#xD;
        -  TDF/FTC 245 mg/200 mg single tablet QD + DRV /cobicistat 800 mg /150 mg single tablet QD&#xD;
           (Arm A, standard regimen),&#xD;
&#xD;
        -  TDF/FTC 245 mg/200 mg single tablet QD + DTG 50 mg QD (Arm B, standard regimen).&#xD;
&#xD;
        -  TDF/FTC 245 mg/200 mg single tablet QD + DRV 800 mg /cobicistat single tablet QD + DTG&#xD;
           50 mg QD (Arm C, experimental regimen).&#xD;
&#xD;
      One-hundred-and-twelve PHI subjects will be recruited for this study among those attending&#xD;
      the outpatient Clinic of Infectious Diseases, Ospedale San Raffaele and other Italian&#xD;
      centres, involved in the INACTION network.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At Screening, potential subjects will perform serology for HIV, ELISA and Western Blot (WB),&#xD;
      to assess Fiebig stage:&#xD;
&#xD;
        -  Stage I: ELISA negative, WB negative, HIV-1 RNA positive.&#xD;
&#xD;
        -  Stage II: ELISA positive for p24, WB negative.&#xD;
&#xD;
        -  Stage III: ELISA positive, WB negative.&#xD;
&#xD;
        -  Stage IV: ELISA positive, WB undetermined.&#xD;
&#xD;
        -  Stage V: ELISA positive, WB partially positive with p31 negative.&#xD;
&#xD;
        -  Stage VI: ELISA positive, WB positive, previous HIV negative test within 6 months&#xD;
&#xD;
      On Day 0 (Baseline-BL), within 0-5 days from screening, subjects will:&#xD;
&#xD;
        -  perform biochemical and haematological tests, virological test (HIV-1 RNA, tropism test,&#xD;
           genotype resistance test), immunological test (CD4+, CD4%, CD8+, CD8%, CD4/CD8).&#xD;
&#xD;
        -  Perform anal and nasal brushing&#xD;
&#xD;
        -  Perform microbiome&#xD;
&#xD;
        -  Have behavioral survey questionnaire administered&#xD;
&#xD;
        -  collect an additional sample of blood (80 mL) to perform the following evaluations:&#xD;
&#xD;
             -  HIV-DNA&#xD;
&#xD;
             -  T cells, B cells and DC subsets&#xD;
&#xD;
             -  HLA-A, B and C&#xD;
&#xD;
             -  Inflammatory markers&#xD;
&#xD;
             -  Pharmacokinetic: Ctrough&#xD;
&#xD;
        -  start one of the study treatment according to randomization&#xD;
&#xD;
             -  Arm A: TDF/FTC 10 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single&#xD;
                tablet QD&#xD;
&#xD;
             -  Arm B: TDF/FTC 25 mg/200 mg single tablet QD +DTG 50 mg QD&#xD;
&#xD;
             -  Arm C: TDF/FTC 10 mg/200 mg single tablet QD +DRV/cobicistat single tablet QD +DTG&#xD;
                50 mg QD&#xD;
&#xD;
      In addition, on Day 0 (Baseline-BL), subjects who will sign an additional specific informed&#xD;
      consent:&#xD;
&#xD;
        -  cerebrospinal fluid (CSF) will be collected to evaluate HIV-1 RNA&#xD;
&#xD;
        -  GALT biopsies will be performed in order to allow the evaluation of viral reservoirs.&#xD;
&#xD;
        -  Lymph nodes biopsies to evaluate immunological subset Following Day 0, subjects will&#xD;
           return for visits at Weeks 2, 4, 8, 12, 24, 36 and 48 or at discontinuation.&#xD;
&#xD;
      HIV-1 RNA levels will be measured and physical examination will be performed at all the&#xD;
      scheduled study visits CD4+, CD4%, CD8+, CD8%, CD4/CD8 will be repeated at Weeks 4, 8, 12,&#xD;
      24, 36, 48 or at discontinuation.&#xD;
&#xD;
      Laboratory safety parameters (complete blood count, renal function, hepatic function, lipids&#xD;
      and glucidic profile) will be tested at Weeks 4, 8, 12, 24, 36, 48 or at discontinuation.&#xD;
&#xD;
      At week 12 and 48 or at discontinuation, an additional blood sample of 80 mL will be&#xD;
      collected to perform the following evaluations:&#xD;
&#xD;
        -  HIV-DNA and viral tropism&#xD;
&#xD;
        -  T, B and DC cells subsets&#xD;
&#xD;
        -  Inflammatory markers At week 2, 4, 8, 12, 24, 36, 48 or at discontinuation a blood&#xD;
           sample of 21 mL will be collected for pharmacokinetic of drugs.&#xD;
&#xD;
      At week 12, 48 or discontinuation a stool sample will be collected to evaluate microbioma.&#xD;
&#xD;
      At week 12 and 48 anal brushing and nasal brushing will be performed to evaluate HIVDNA and&#xD;
      pharmacokinetic analysis.&#xD;
&#xD;
      At week 12 and 48 behavioral survey questionnaire will be administered to the patient.&#xD;
&#xD;
      At week 12, or at discontinuation, in subjects who will have signed the specific additional&#xD;
      informed consent:&#xD;
&#xD;
        -  liquor will be collected to evaluate HIV-1 RNA and drugs concentration in central&#xD;
           nervous system.&#xD;
&#xD;
        -  CSF will be collected to evaluate HIV-1 RNA and drugs concentration in central nervous&#xD;
           system.&#xD;
&#xD;
        -  GALT biopsies and lymph nodes biopsy will be performed in order to allow the evaluation&#xD;
           of viral reservoirs.&#xD;
&#xD;
      Subjects will complete the study when they will reach week 48 on their assigned regimen. At&#xD;
      the end of the study, they will continue assigned treatment in arm A and B; if the study will&#xD;
      show a superiority of ARM C, the patients in this arm will continue the regimen. In case of&#xD;
      non superiority they will be switch to triple therapy. The last patient visit is the last&#xD;
      on-study visit or date of death or lost-to follow-up or discontinuation for any reason,&#xD;
      whichever occurs last during the conduction of the study.&#xD;
&#xD;
      Considering that the patients' enrollment will last 96 weeks, the overall length of the trial&#xD;
      will be 144 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">June 14, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomised in a ratio 10:10:8 to be treated with one of the three antiretroviral regimens:&#xD;
TDF/FTC 245 mg/200 mg single tablet QD + DRV /cobicistat 800 mg /150 mg single tablet QD (Arm A, standard regimen),&#xD;
TDF/FTC 245 mg/200 mg single tablet QD + DTG 50 mg QD (Arm B, standard regimen).&#xD;
TDF/FTC 245 mg/200 mg single tablet QD + DRV 800 mg /cobicistat single tablet QD + DTG 50 mg QD (Arm C, experimental regimen).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of total HIV-DNA level from baseline to 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>The primary objective of the study is to compare the proviral DNA change in patients who started three different antiretroviral treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>weeks 12, 24 and 48</time_frame>
    <description>proportion of patients with HIV-1 RNA &lt;50 copies/mL at week 24 and week 48;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to achieve undetectable viral load</measure>
    <time_frame>week 12 and week 48</time_frame>
    <description>HIV-1 RNA &lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HIV-DNA</measure>
    <time_frame>week 12 and week 48</time_frame>
    <description>the change of total copies/mL OF HIV-DNA level from baseline to 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HIV-1 RNA in CSF</measure>
    <time_frame>week 12 and 48</time_frame>
    <description>the change of total copies/mL of HIV-RNA level in cerebrospinal fluid</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>A: SYMTUZA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAF/FTC 245 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single tablet QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: DESCOVY+DOLUTEGRAVIR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAF/FTC 245 mg/200 mg single tablet QD+DTG 50 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: SYMTUZA+DOLUTEGRAVIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAF/FTC 245 mg/200 mg single tablet QD+DRV/cobicistat single tablet QD + +DTG 50 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>SYMTUZA</intervention_name>
    <description>DESCOVY+REZOLSTA</description>
    <arm_group_label>A: SYMTUZA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>DESCOVY+DOLUTEGRAVIR</intervention_name>
    <description>DESCOVY+DOLUTEGRAVIR</description>
    <arm_group_label>B: DESCOVY+DOLUTEGRAVIR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>SYMTUZA+DOLUTEGRAVIR</intervention_name>
    <description>DESCOVY+REZOLSTA+DTG</description>
    <arm_group_label>C: SYMTUZA+DOLUTEGRAVIR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Subjects must be at least 18 years of age at the time of randomization, of either sex&#xD;
             and of any race.&#xD;
&#xD;
          -  Primary HIV Infection defined according to Fiebig's classification.&#xD;
&#xD;
          -  Subjects must have given written informed consent and must be able to adhere to dose&#xD;
             and visit schedules.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must agree to use a medically accepted&#xD;
             method of contraception.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must have a negative serum beta-hCG&#xD;
             pregnancy test at Screening, and a negative urine beta-HCG pregnancy test on Day 1&#xD;
             prior to dosing.&#xD;
&#xD;
          -  A female, may be eligible to enter and participate in the study if she:&#xD;
&#xD;
               1. is of non-child-bearing potential defined as either post-menopausal (12 months of&#xD;
                  spontaneous amenorrhea and â‰¥ 45 years of age) or physically incapable of becoming&#xD;
                  pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy;&#xD;
&#xD;
               2. is of child-bearing potential with a negative pregnancy test at both Screening&#xD;
                  and Day 1 and agrees to use one of the following methods of contraception to&#xD;
                  avoid pregnancy:&#xD;
&#xD;
          -  Complete abstinence from penile-vaginal intercourse from 2 weeks prior to&#xD;
             administration of IP, throughout the study, and for at least 2 weeks after&#xD;
             discontinuation of all study medications;&#xD;
&#xD;
          -  Double barrier method (male condom/spermicide, male condom/diaphragm,&#xD;
             diaphragm/spermicide);&#xD;
&#xD;
          -  Any intrauterine device (IUD) with published data showing that the expected failure&#xD;
             rate is &lt;1% per year (not all IUDs meet this criterion, see Appendix 4 for an example&#xD;
             listing of approved IUDs);&#xD;
&#xD;
          -  Male partner sterilization confirmed prior to the female subject's entry into the&#xD;
             study, and this male is the sole partner for that subject;&#xD;
&#xD;
          -  Approved hormonal contraception for subjects randomized to arm B (TDF/FTC + DTG)&#xD;
&#xD;
          -  Approved hormonal contraception and a barrier method for subjects randomized to arm A&#xD;
             (TDF/FTC +DRV/cobicistat) and C (TDF/FTC +DRV/cobicistat +DTG)&#xD;
&#xD;
          -  Any other method with published data showing that the expected failure rate is &lt;1% per&#xD;
             year.&#xD;
&#xD;
          -  Any contraception method must be used consistently, in accordance with the approved&#xD;
             product label and for at least 2 weeks after discontinuation of IP. -Approved hormonal&#xD;
             contraception for subjects randomized to the treatment groups should be specified.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Female subjects of childbearing potential who are breastfeeding, pregnant, or planning&#xD;
             to become pregnant.&#xD;
&#xD;
          -  Subjects with active opportunistic infection or malignancy.&#xD;
&#xD;
          -  Subjects positive for Hepatitis B at screening (+HBsAg), or anticipated need for&#xD;
             Hepatitis C virus (HCV) therapy during the study.&#xD;
&#xD;
          -  Subjects with known liver cirrhosis.&#xD;
&#xD;
          -  Subjects with any clinically significant condition or situation other than the&#xD;
             condition being studied that, in the opinion of investigator, would interfere with the&#xD;
             study evaluations or optimal participation.&#xD;
&#xD;
          -  Subjects with allergy/sensitivity to drugs or its excipients.&#xD;
&#xD;
          -  History or presence of allergy to the study drugs or their components&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) 5 times the upper limit of normal (ULN), OR ALT 3xULN&#xD;
             and bilirubin 1.5xULN (with &gt;35% direct bilirubin)&#xD;
&#xD;
          -  Unstable liver disease (as defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice),&#xD;
             cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or&#xD;
             asymptomatic gallstones)&#xD;
&#xD;
          -  Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh&#xD;
             classification&#xD;
&#xD;
          -  Subject has creatinine clearance of &lt;70 mL/min via Cockroft-Gault method&#xD;
&#xD;
          -  Hepatic failure (Child-Plug grade C)&#xD;
&#xD;
          -  Use of not modifiable concomitant drugs: carbamazepine, fenitoine, fenobarbital,&#xD;
             rifampicine, Hypericum perforatum, dofelitide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GIUSEPPE TAMBUSSI</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SILVIA NOZZA</last_name>
    <phone>0226437961</phone>
    <phone_ext>+39</phone_ext>
    <email>nozza.silvia@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SILVIA NOZZA</last_name>
      <phone>+39.0226437961</phone>
      <email>nozza.silvia@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>MARIA RITA PARISI</last_name>
      <phone>+39.0226433646</phone>
      <email>parisi.mariarita@hsr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>ADRIANO LAZZARIN, MD</investigator_full_name>
    <investigator_title>HEAD OF INFECTIOUS DISEASES CLINIC</investigator_title>
  </responsible_party>
  <keyword>antiretroviral drugs</keyword>
  <keyword>HIV viral reservoir</keyword>
  <keyword>HIV acute infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

